AbCellera Biologics (ABCL) PT Lowered to $5 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Gary Nachman lowered the price target on AbCellera Biologics (NASDAQ: ABCL) to $5.00 (from $12.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
